U.S. Biotech Stock News

AtaiBeckley (ATAI) recently posted quarterly results that surpassed market expectations, reporting an earnings per share loss of US$0.06 and revenue of US$1.07m, along with continued progress across its mental health treatment pipeline. See our latest analysis for AtaiBeckley. AtaiBeckley’s recent earnings surprise and pipeline updates have come alongside a 13.24% 7 day share price return and 13.57% 30 day share price return, while the 1 year total shareholder return of about 7x points to...

In recent weeks, Alliant Energy announced a US$1.00 billion at-the-market equity offering to fund data center and AI/cloud-related infrastructure, alongside governance changes such as a mandatory director retirement age of 70 and a target of 75% independent board representation. The same initiatives have drawn rising environmental and community opposition in Wisconsin and Iowa, highlighting that Alliant’s push into digital infrastructure could reshape both its growth profile and its...

Acadia Pharmaceuticals has recently confirmed that DAYBUE STIX, a dye- and preservative-free powder formulation of trofinetide for Rett syndrome in patients aged two and older, is now broadly available in the United States following its FDA approval in December 2025. The addition of a bioequivalent, more flexible powder option that aligns with expert recommendations for real-world trofinetide use could strengthen DAYBUE’s role in Rett syndrome care and deepen Acadia’s engagement with this...

Confirmation that TMC the metals (TMC) has a complete consolidated deep sea mining application with U.S. regulators, along with new NOAA rules that can shorten permitting timelines, has pushed this early stage minerals story back into focus. See our latest analysis for TMC the metals. The confirmation of TMC's complete U.S. mining application and the new NOAA rules arrive after a sharp share price reset, with a 30 day share price return of a 19.9% decline and a 90 day share price return of a...

Enovix recently reported quarterly results that topped revenue and adjusted loss expectations while also outlining first-quarter guidance, and reports emerged of a potential partnership with Meta-Bounds to boost battery life for lightweight AR glasses by an estimated 61%. This possible collaboration underscores how Enovix’s battery technology may fit into emerging augmented reality devices, complementing its improving, though still loss-making, financial profile. Now we’ll examine how the...

What Enova International (ENVA) investors are watching now Enova International (ENVA) has drawn fresh attention as its recent share performance contrasts sharply between time frames, with a modest move over the past month alongside a 14% decline in the past 3 months. See our latest analysis for Enova International. At a share price of $138.77, Enova International’s recent 5.7% 7 day share price return contrasts with a 14.3% year to date share price decline. The 1 year total shareholder return...

Ultragenyx Pharmaceutical (RARE) is back in focus after the FDA accepted its resubmitted biologics license application for UX111, a gene therapy for Sanfilippo syndrome Type A, with an accelerated approval decision expected later this year. See our latest analysis for Ultragenyx Pharmaceutical. The FDA milestones around UX111 and UX016 have arrived against a mixed backdrop, with a sharp 18.5% 7 day share price return contrasting with a 1 year total shareholder return of 28.84% and a 5 year...

T-Mobile US (NasdaqGS:TMUS) launched an "Unf*! Your Bills" Mint Mobile bundle, offering premium wireless and 5G home internet for US$45 per month with a 5 year no bill increase guarantee. The bundle targets traditional cable providers with contract free pricing and a high profile campaign featuring Marie Kondo. T-Mobile expanded 5G partnerships, supplying low latency edge connectivity for Serve Robotics' new AI conversational robot. The company is also working with Motorola Solutions to...

Aura Minerals (AUGO) has drawn fresh attention after publishing updated Mineral Reserves and Mineral Resources for six operating mines and several projects. The update reflects new drilling data, revised geology, and updated mine plans and economic assumptions. See our latest analysis for Aura Minerals. The updated reserve and resource figures have landed alongside a sharp shift in market sentiment, with the share price at US$89.02 and a 7 day share price return of 25.56% contributing to...

Corteva recently reached a new all-time high, supported by overwhelmingly positive analyst sentiment that now skews toward “Buy” ratings from major firms. Low short interest and strong participation from both Wall Street and individual investors highlight how sentiment alone can materially influence Corteva’s trading activity. We’ll now explore how this wave of bullish analyst support could reshape Corteva’s investment narrative and perceived risk-reward balance. This technology could...

In late March and early April 2026, Thermo Fisher Scientific launched new Gibco cell therapy and CHOvantage biologics platforms, unveiled the Glacios 3 cryo-TEM, and entered a collaboration with SHL Medical to expand U.S.-based drug-device combination manufacturing capabilities. Together, these moves deepen Thermo Fisher’s role across high-value biomanufacturing and advanced research workflows, reinforcing its position as an integrated partner to biopharma and cell and gene therapy...

In early April 2026, Nutanix announced a wave of product and partner updates, including new multitenant cloud capabilities for service providers, a certified integration between Nutanix Database Service and MongoDB Ops Manager, and a planned integration of NetApp’s enterprise storage with the Nutanix Cloud Platform and AHV hypervisor. These moves collectively target VMware partner migrations, simplify large-scale MongoDB operations, and broaden infrastructure choices through NetApp,...

Novavax: recent performance snapshot for retail investors Novavax (NVAX) has drawn attention after recent share price swings, with the stock closing at US$7.97 and showing mixed returns over the past month and past 3 months. For context, the company reports annual revenue of US$1.12b from recombinant vaccines, including its commercialized COVID-19 product Nuvaxovid and the R21 Matrix-M adjuvant malaria vaccine. See our latest analysis for Novavax. The recent 1 day share price return of 3.51%...

Teledyne Technologies (TDY) is back in focus after a series of new defense, marine, and space contracts, including an upgrade to its Prism SKR autonomy software that reframes how guided systems handle mission execution. See our latest analysis for Teledyne Technologies. Those defense, marine, and space wins come as Teledyne Technologies’ share price sits at US$632.01, with a 7 day share price return of 8.21% and a 90 day share price return of 18.64%, while the 1 year total shareholder return...

Green Brick Partners (GRBK) is drawing fresh investor attention after announcing Rainwater Crossing, a master planned community in Celina, Texas that combines new model homes, multiple builders, extensive amenities and public art. See our latest analysis for Green Brick Partners. Alongside the Rainwater Crossing announcement, Green Brick Partners’ share price has moved to US$66.26, with a 7 day share price return of 5.59% but a 30 day share price return of a 3.00% decline. The 1 year total...

Wondering whether Vera Therapeutics at around US$40.45 is still offering value, or if the easy gains are behind it? This article is designed to help you frame that question clearly. The stock has returned 6.2% over the last week and 3.5% over the last month, while year to date it is down 16.8% but up 102.8% over the past year and a very large amount over three years. This naturally raises questions about what is already priced in. Recent coverage has focused on Vera Therapeutics as investors...

Align Technology (ALGN) is back in focus after a run of analyst upgrades tied to its recent earnings performance, with revenue and net income both showing year over year growth and valuation metrics attracting fresh investor attention. See our latest analysis for Align Technology. At a share price of US$171.87, Align’s recent 7 day share price return of 3.37% and year to date share price return of 10.15% sit against a 1 year total shareholder return of 12.08%, while the 3 year and 5 year...

Why Red Rock Resorts is on investors’ radar today Red Rock Resorts (RRR) has drawn investor attention after recent share price moves, with the stock up 1.3% over the past week but showing a 3.4% decline over the past month. See our latest analysis for Red Rock Resorts. While the recent 6.8% 7 day share price return stands out against an 11.5% year to date share price decline, the 1 year total shareholder return of 53.0% shows that longer term investors have still seen strong gains. If recent...

In March 2026, Accenture announced that Hormel Foods had completed the integration of o9 Solutions’ AI-powered demand and supply planning platform across more than 70 dry and refrigerated network sites, unifying previously disconnected planning tools for its complex global supply chain. This move gives Hormel Foods an enterprise-wide “digital brain” to better synchronize demand signals with inventory, production, and logistics decisions across brands from SPAM and SKIPPY to PLANTERS and...

Why Exelon (EXC) is on investors’ radar right now Exelon (EXC) has drawn attention after recent share performance, with a modest negative move over the past week and month, alongside a positive total return over the past 3 months and year. For investors tracking utilities, Exelon’s current share price of $48.94, market value of about $50.5b, and value score of 3 provide a starting point for thinking about how the stock fits into a broader portfolio. See our latest analysis for Exelon. Recent...

Crinetics Pharmaceuticals (CRNX) recently submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, supported by data from 18 clinical trials, including two Phase 3 studies that met all primary and secondary endpoints. See our latest analysis for Crinetics Pharmaceuticals. The Brazil filing arrives after a strong run in recent days, with a 7 day share price return of 10.01% partly offsetting a weaker year to date share price return of 19.32% and contrasting with a 1...

In late March 2026, Guardant Health announced that its InfinityAI real-world evidence platform was used alongside clinical trial data to support Japan’s approval of Daiichi Sankyo’s ENHERTU for treating HER2-positive advanced or recurrent solid cancers refractory or intolerant to standard therapies. This use of InfinityAI highlights how Guardant’s clinicogenomic data and artificial intelligence can help regulators assess outcomes in genomic subpopulations that are difficult to enroll in...

Builders FirstSource (BLDR) is back in focus after a recent quarter in which it missed analysts' revenue and EBITDA estimates but still raised full-year guidance, a rare move among peers. See our latest analysis for Builders FirstSource. The share price tells a mixed story: the 1-day share price return of 3.7% and 7-day gain of 4.1% come after a 30-day share price decline of 11.9% and a 1-year total shareholder return of 31% in the red. This suggests momentum has cooled even as guidance...

Investor focus on FTAI Aviation (FTAI) sharpened after the U.S. President signaled willingness to ease military tensions, a shift that coincided with a 4% stock move and calmer energy and industrial sector sentiment. See our latest analysis for FTAI Aviation. For context, FTAI Aviation’s 1-day share price return of 1.70%, 7-day share price return of 7.89% and year to date share price return of 17.34% sit against a very large 1-year total shareholder return. This suggests momentum has been...